Skip to main content
NCBI home page
Springer logoLink to Springer
. 2022 Sep 27;27(11):1793. doi: 10.1007/s10147-022-02237-2

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

Kenjiro Aogi 1,✉, Kenichi Watanabe 2, Masahiro Kitada 3, Takafumi Sangai 4, Shoichiro Ohtani 5, Tomoyuki Aruga 6, Hidetoshi Kawaguchi 7, Tomomi Fujisawa 8, Shigeto Maeda 9, Takashi Morimoto 10, Nobuaki Sato 11, Shintaro Takao 12, Satoshi Morita 13, Norikazu Masuda 14, Masakazu Toi 15, Shinji Ohno 16
PMCID: PMC9606053  PMID: 36166110

Correction to: International Journal of Clinical Oncology (2021) 26:1229–1236 10.1007/s10147-021-01920-0

In the original publication, the name of fourth and seventh authors were incorrectly published as: Takashi Sangai and Hidetoshi Kawagichi. The correct version of names are: Takafumi Sangai and Hidetoshi Kawaguchi as given in this Correction.

The original publication has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from International Journal of Clinical Oncology are provided here courtesy of Springer

RESOURCES